Immunoadsorption in thrombangiitis obliterans - A promising therapeutic optionresults of a consecutive patient cohort treated in clinical routine care;Immunadsorption bei Thrombangiitis obliterans - eine vielversprechende therapeutische Option. Behandlungsergebnisse einer konsekutiven Patientenkohorte der klinischen Routineversorgung

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 137, Issue 5, 2012, Pages 460-465

  Klein Weigel, P F ^a   Koning C ^b   Hartwig A ^b   Kruger K ^b   Gutsche Petrak, B ^b   Dreusicke, S ^a   Thieme, U ^c   Enke Melzer, K ^d   Urbach, B ^c   Kron, J ^c  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b German Red Cross Hospital   (Germany)

^c KfH Nierenzentrum   (Germany)

^d Helios Kliniken Emil von Behring   (Germany)

Author keywords

Buergers disease; critical limb ischaemia; immune therapy; peripheral arterial occlusion disease; thrombangiitis obliterans; vascular surgery

Indexed keywords

ADULT; ARTICLE; BUERGER DISEASE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINGER; FOLLOW UP; FOOT; HUMAN; ISCHEMIA; MALE; MIDDLE AGED; RAYNAUD PHENOMENON; TOE; VASCULARIZATION;

ADULT; COHORT STUDIES; FEMALE; FINGERS; FOLLOW-UP STUDIES; FOOT; HUMANS; IMMUNOSORBENT TECHNIQUES; ISCHEMIA; MALE; MIDDLE AGED; RAYNAUD DISEASE; THROMBOANGIITIS OBLITERANS; TOES;

EID: 84868485669     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0032-1315141     Document Type: Article

References (25)

1. Zünd G., Enzler M., Schimmer R. et al. Differentialdiagnose der Ischämie der unteren Extremitäten bei jungen Erwachsenen. Zentralbl Chir: 1993; 118 622 627 (Pubitemid 23324248)
2. Olin J. W. Thromboangiitis obliterans (Buergers disease). N Engl J Med: 2000; 343 864 869
3. Mills J. L. Buergers disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg: 2003; 16 179 189
4. Schellong S. M., Bernhards J., Ensslen F. et al. Intestinal type of thromboangiitis obliterans (Buergers disease). J Intern Med: 1994; 235 69 73 (Pubitemid 24192715)
5. Börner C., Heidrich H. Long-term follow-up of thromboangiitis obliterans. Vasa: 1998; 27 80 86 (Pubitemid 28232156)
6. Puéchal X., Fiessinger J. N. Thromboangiitis obliterans or Buergers disease: challenges for the rheumatologist. Rheumatology (Oxford): 2007; 46 192 199 (Pubitemid 46189775)
7. Fazeli B., Rezaee S. A. A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame? Vascular: 2011; 19 141 153
8. Eichhorn J., Sima D., Lindschau C. et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci: 1998; 315 17 23 (Pubitemid 28047565)
9. Halacheva K. S., Manolova I. M., Petkov D. P. et al. Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans (Buergers disease). Scand J Immunol: 1998; 48 544 550 (Pubitemid 28505681)
10. Kobayashi M., Ito M., Nakagawa A. et al. Immunohistochemical analysis of arterial wall cellular infiltration in Buergers disease. J Vasc Surg: 1999; 29 451 458 (Pubitemid 29152267)
11. Kobayashi M., Nishikimi N., Komori K. Current pathological and clinical aspects of Buergers disease in Japan. Ann Vasc Surg: 2006; 20 148 156 (Pubitemid 43029874)
12. Gulati S. M., Madhra K., Thusoo T. K. et al. Autoantibodies in thromboangiitis obliterans (Buergers Disease). Angiology: 1982; 33 642 651 (Pubitemid 12004935)
13. Hershko A. Y., Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann NY Acad Sci: 2005; 1051 635 646 (Pubitemid 41362791)
14. Moreso F., Poveda R., Gil-Vernet S. et al. Therapeutic immunoadsorption in Goodpasture disease. Med Clin: 1995; 105 59 61
15. Psaridi-Linardaki L., Trakas N., Mamalaki A. et al. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen specific therapeutic strategy. J Neuroimmunol: 2005; 159 183 191 (Pubitemid 40126191)
16. Stummvoll G. H., Aringer M., Smolen J. S. et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis: 2005; 64 1015 1021 (Pubitemid 40909515)
17. Bartel G., Wahrmann M., Regele H. et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant: 2010; 10 2033 2042
18. Palmer A., Taube D., Welsh K. et al. Removal of anti HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet: 1989; 1 10 12 (Pubitemid 19035213)
19. Dörffel W. V., Felix S. B., Wallukat G. et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation: 1997; 95 1994 1997 (Pubitemid 27184263)
20. Felix S. B., Staudt A., Dörffel W. V. et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three month results from a randomized study. J Am Coll Cardiol: 2000; 35 1590 1598 (Pubitemid 30307505)
21. Baumann G., Stangl V., Klein-Weigel P. et al. Successful treatment of thromboangiitis obliterans (Buergers disease) with immunoadsorption: results of a pilot study. Clin Res Cardiol: 2011; 100 683 690
22. Shionoya S. Buergers Disease (Thrombangiitis obliterans). In: Rutherford R. B. ed. Vascular Surgery. 3rd ed. Philadelphia WB Saunders: 1989; 207 217
23. Olin J. W., Young J. R., Graor R. A. et al. The changing clinical spectrum of thrombangiitis obliterans (Buergers disease). Circulation: 1990; 825 (Suppl IV) 3 8
24. Fazeli B., Ravari H., Assadi R. Natural history definition and a suggested clinical approach to Buergers disease: a case-control study with survival analysis. Vascular: 2012; 20 198 202
25. Dargon P. T., Landry G. J. Buergers disease. Ann Vasc Surg: 2012; 26 871 880